Proveris Scientific Corporation

Proveris Scientific Corporation, based in the US, provides cutting-edge testing solutions and laboratory services for orally inhaled and nasal drug products, enhancing drug delivery precision and performance. Founded in 1995, Proveris Scientific Corporation specializes in testing solutions for pharmaceuticals and device manufacturers. It has maintained its core focus on orally inhaled and nasal drug products while continuously adapting to meet market demands. The company is headquartered in the United States and has successfully completed a funding round involving an acquisition by Investindustrial in January 2026, which enhances its capacity in pharmaceutical testing.

The founder's history is not publicly detailed, nor are there known subsidiaries or prior mergers. Proveris Scientific Corporation specializes in providing advanced testing solutions and laboratory services for orally inhaled and nasal drug products (OINDPs). Their core offerings include innovative testing platforms such as SprayVIEW® measurement systems, Vereo® actuators, and the Viota® software platform, designed to facilitate precise measurement and analysis of spray characteristics, ensuring optimal drug delivery and performance. The company’s products cater to a diverse clientele, including top innovator and generic pharmaceutical companies, device manufacturers, contract development organizations (CDOs), contract research organizations (CROs), contract manufacturing organizations (CMOs), and regulatory agencies across various global markets including North America, Europe, and Asia.

Proveris's technology helps clients streamline product development, optimize device performance, and enhance regulatory compliance, ultimately improving patient outcomes through effective inhalation therapies. Proveris Scientific Corporation generates revenue primarily through the sale of its testing equipment, laboratory services, and software solutions to its client base in the pharmaceutical and device manufacturing sectors. Transactions typically occur on a B2B basis, where clients procure equipment such as the SprayVIEW® systems and Vereo® actuators, often complemented by ongoing training and support services. The company's flagship products are integrated into client workflows, promoting efficiency and compliance in drug development processes.

Revenue is structured around direct sales of products, service contracts for ongoing support, and partnerships for collaborative projects in pharmaceutical testing. Each transaction reflects the commitment to delivering innovative, high-quality solutions that meet specific client needs within the OINDP market. Proveris Scientific Corporation is poised for growth following its acquisition by Investindustrial in January 2026. The acquisition will enable the company to expand its pharmaceutical testing offerings and accelerate its growth trajectory.

Plans include the development of new products tailored to enhance testing capabilities, with specific launch dates to be announced. Additionally, the company aims to penetrate new geographic markets, with targeted expansions planned in Europe and Asia over the next few years. The financial backing from the acquisition will support these initiatives, enabling investment in technology and market reach.